Id: acc0539
Group: 1sens
Protein: Smad2
Gene Symbol: SMAD2
Protein Id: Q15796
Protein Name: SMAD2_HUMAN
PTM: phosphorylation
Site: Thr8
Site Sequence: --MSSILPFTPPVVKRLLGWK
Disease Category: Cancer
Disease: Pancreas Cancer
Disease Subtype: PDAC
Disease Cellline: BxPC-3
Disease Info:
Drug: metformin
Drug Info: "Metformin is an oral antihyperglycemic agent used primarily in the treatment of type 2 diabetes, which works by reducing hepatic glucose production and enhancing peripheral insulin sensitivity."
Effect: modulate
Effect Info: "Metformin reduces the phosphorylation of Smad2/3 in pancreatic cancer cells, thereby inhibiting tumors."
Note:
Score: 4.0
Pubmed(PMID): 29956804
Sentence Index:
Sentence:

Sequence & Structure:

MSSILPFTPPVVKRLLGWKKSAGGSGGAGGGEQNGQEEKWCEKAVKSLVKKLKKTGRLDELEKAITTQNCNTKCVTIPSTCSEIWGLSTPNTIDQWDTTGLYSFSEQTRSLDGRLQVSHRKGLPHVIYCRLWRWPDLHSHHELKAIENCEYAFNLKKDEVCVNPYHYQRVETPVLPPVLVPRHTEILTELPPLDDYTHSIPENTNFPAGIEPQSNYIPETPPPGYISEDGETSDQQLNQSMDTGSPAELSPTTLSPVNHSLDLQPVTYSEPAFWCSIAYYELNQRVGETFHASQPSLTVDGFTDPSNSERFCLGLLSNVNRNATVEMTRRHIGRGVRLYYIGGEVFAECLSDSAIFVQSPNCNQRYGWHPATVCKIPPGCNLKIFNNQEFAALLAQSVNQGFEAVYQLTRMCTIRMSFVKGWGAEYRRQTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

SMAD2-Ser118
Cancer Intensity
BRCA
COAD -1.1
HGSC
ccRCC 0.246
GBM
HNSC
LUAD
LUSC 0.854
non_ccRCC
PDAC
UCEC
SMAD2-Thr172
Cancer Intensity
BRCA 0.002
COAD -0.816
HGSC 1.954
ccRCC -0.467
GBM
HNSC -0.115
LUAD -0.6
LUSC 0.334
non_ccRCC -1.011
PDAC -0.765
UCEC 1.485

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - A Salivary adenoid cystic carcinoma Phosphorylation 21441221
K 451 D Renal fibrosis Acetylation 37777567
T 220 D Pancreatic ductal adenocarcinoma Phosphorylation 27014871
S 250 D Pancreatic ductal adenocarcinoma Phosphorylation 27014871
- - D Hepatocellular carcinoma Ubiquitination 35509688
- - P Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 24334458
- - P Pre-eclampsia Phosphorylation 22832245
- - P Gastric cancer Ubiquitination 32226309
S 465 U Head and neck squamous cell carcinoma Phosphorylation 21281788 ;  35022323
S 465 U Marfan syndrome Phosphorylation 15731757
S 467 U Head and neck squamous cell carcinoma Phosphorylation 21281788 ;  35022323
S 467 U Marfan syndrome Phosphorylation 15731757
T 220 U Breast cancer Phosphorylation 33051597
- - U Ovarian cancer Phosphorylation 35293014
S 465 U Gastric cancer Phosphorylation 23934187
- - U Breast cancer Ubiquitination 33649832

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
Q15796 SMAD2 P Thr8 SSILPFT(ph)PPVVK A431 Afatinib 7.9807 -
Q15796 SMAD2 P Thr8 SSILPFT(ph)PPVVK A431 Afatinib 7.0973 -
Q15796 SMAD2 P Thr8 SSILPFT(ph)PPVVK A431 Afatinib 8.768 -
Q15796 SMAD2 P Thr8 SSILPFT(ph)PPVVK A431 Afatinib 7.7933 -
Q15796 SMAD2 P Thr8 SSILPFT(ph)PPVVK A431 Dasatinib 6.9025 -
Q15796 SMAD2 P Thr8 SSILPFT(ph)PPVVK A431 Dasatinib 6.5827 -
Q15796 SMAD2 P Thr8 SSILPFT(ph)PPVVK A431 Dasatinib 6.287 -
Q15796 SMAD2 P Thr8 SSILPFT(ph)PPVVK A431 Gefitinib 3.159 -
Q15796 SMAD2 P Thr8 SSILPFT(ph)PPVVK A431 Gefitinib 2 -
Q15796 SMAD2 P Thr8 SSILPFT(ph)PPVVK A431 Gefitinib 6.2915 -
Q15796 SMAD2 P Thr8 SSILPFT(ph)PPVVK HeLa SAHA 9.42 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: